Calcitonin has been successfully delivered to the systemic circulation intranasally [7, 8] and is now available as Miacalcin® (Novartis Pharmaceuticals Corp, East Hanover, NJ, USA) nasal spray to treat postmenopausal osteoporosis in females greater than 5 years post menopause. Here, CALCA is linked to postmenopausal osteoporosis.